Toby Kent

567 total citations
21 papers, 409 citations indexed

About

Toby Kent is a scholar working on Molecular Biology, Immunology and Rheumatology. According to data from OpenAlex, Toby Kent has authored 21 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Immunology and 5 papers in Rheumatology. Recurrent topics in Toby Kent's work include Receptor Mechanisms and Signaling (9 papers), Psoriasis: Treatment and Pathogenesis (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Toby Kent is often cited by papers focused on Receptor Mechanisms and Signaling (9 papers), Psoriasis: Treatment and Pathogenesis (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Toby Kent collaborates with scholars based in United Kingdom, Switzerland and United States. Toby Kent's co-authors include Steven J. Charlton, Juliet Leighton-Davies, Alexandre Trifilieff, Mark R. Dowling, David A. Sykes, Paul D. Wright, Paul J. Groot‐Kormelink, Martin Gosling, Elizabeth M. Rosethorne and David D’Cruz and has published in prestigious journals such as PLoS ONE, Journal of Pharmacology and Experimental Therapeutics and Molecular Pharmacology.

In The Last Decade

Toby Kent

21 papers receiving 399 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Toby Kent United Kingdom 10 204 83 81 76 72 21 409
James Harrison United Kingdom 16 238 1.2× 101 1.2× 21 0.3× 339 4.5× 82 1.1× 20 695
Guillaume Arguin Canada 16 236 1.2× 37 0.4× 28 0.3× 42 0.6× 44 0.6× 26 494
Elena Calama Spain 12 107 0.5× 134 1.6× 66 0.8× 63 0.8× 44 0.6× 23 323
Margaret Nguyen United States 10 132 0.6× 54 0.7× 32 0.4× 46 0.6× 42 0.6× 15 442
Håkan Bergstrand Sweden 13 314 1.5× 192 2.3× 156 1.9× 191 2.5× 41 0.6× 40 655
Anja Herrnreiter United States 11 145 0.7× 170 2.0× 71 0.9× 61 0.8× 29 0.4× 22 399
Valerie C. Lowe United States 12 225 1.1× 56 0.7× 20 0.2× 52 0.7× 93 1.3× 21 434
Paul C. Canniff United States 11 243 1.2× 45 0.5× 41 0.5× 147 1.9× 67 0.9× 19 518
Hana Yamane Japan 8 123 0.6× 165 2.0× 32 0.4× 172 2.3× 27 0.4× 9 494
M A Giembycz United Kingdom 12 254 1.2× 294 3.5× 138 1.7× 123 1.6× 112 1.6× 14 627

Countries citing papers authored by Toby Kent

Since Specialization
Citations

This map shows the geographic impact of Toby Kent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toby Kent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toby Kent more than expected).

Fields of papers citing papers by Toby Kent

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toby Kent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toby Kent. The network helps show where Toby Kent may publish in the future.

Co-authorship network of co-authors of Toby Kent

This figure shows the co-authorship network connecting the top 25 collaborators of Toby Kent. A scholar is included among the top collaborators of Toby Kent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toby Kent. Toby Kent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Conaghan, Philip G., Karel Pavelká, Song‐Chou Hsieh, et al.. (2022). Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials. Rheumatology Advances in Practice. 7(1). rkad017–rkad017. 4 indexed citations
2.
Coates, Laura C., Toby Garrood, Nicola Gullick, et al.. (2021). P174 Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. Lara D. Veeken. 60(Supplement_1). 1 indexed citations
3.
4.
5.
Yosipovitch, Gil, Adam Reich, Martin Steinhoff, et al.. (2018). Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies. Dermatology and Therapy. 8(4). 621–637. 13 indexed citations
6.
Kent, Toby, et al.. (2017). Burden of illness in systemic lupus erythematosus: results from a UK patient and carer online survey. Lupus. 26(10). 1095–1100. 33 indexed citations
7.
Kent, Toby, et al.. (2015). THE ECONOMIC BURDEN OF MINOR AILMENTS ON THE NATIONAL HEALTH SERVICE IN THE UK - Selfcare Journal. 6 indexed citations
8.
Trifilieff, Alexandre, Brian Ethell, David A. Sykes, et al.. (2015). Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model. Toxicology and Applied Pharmacology. 287(1). 9–16. 4 indexed citations
9.
Rosethorne, Elizabeth M., et al.. (2015). Functional desensitization of the β2 adrenoceptor is not dependent on agonist efficacy. Pharmacology Research & Perspectives. 3(1). e00101–e00101. 10 indexed citations
10.
McPate, Mark J., Gurdip Bhalay, Martin Gosling, et al.. (2014). The Development of Automated Patch Clamp Assays for Canonical Transient Receptor Potential Channels TRPC3, 6, and 7. Assay and Drug Development Technologies. 12(5). 282–292. 4 indexed citations
11.
Bill, Anke, Elizabeth M. Rosethorne, Toby Kent, et al.. (2014). High Throughput Mutagenesis for Identification of Residues Regulating Human Prostacyclin (hIP) Receptor Expression and Function. PLoS ONE. 9(6). e97973–e97973. 8 indexed citations
12.
Dombrecht, Bruno, Jordan R. Willis, Klaas Van Den Heede, et al.. (2014). Potent and Efficacious Inhibition of CXCR2 Signaling by Biparatopic Nanobodies Combining Two Distinct Modes of Action. Molecular Pharmacology. 87(2). 251–262. 61 indexed citations
13.
Mackenzie, Amanda E., Gianluigi Caltabiano, Toby Kent, et al.. (2013). The Antiallergic Mast Cell Stabilizers Lodoxamide and Bufrolin as the First High and Equipotent Agonists of Human and Rat GPR35. Molecular Pharmacology. 85(1). 91–104. 59 indexed citations
14.
Akhlaq, Mohammed Shahid, et al.. (2013). The Use of Cold Plasma Technology to Reduce Carryover in Screening Assays. SLAS TECHNOLOGY. 18(4). 269–275. 2 indexed citations
15.
Sykes, David A., Mark R. Dowling, Juliet Leighton-Davies, et al.. (2012). The Influence of Receptor Kinetics on the Onset and Duration of Action and the Therapeutic Index of NVA237 and Tiotropium. Journal of Pharmacology and Experimental Therapeutics. 343(2). 520–528. 92 indexed citations
16.
Groot‐Kormelink, Paul J., et al.. (2012). Quantitative GPCR and ion channel transcriptomics in primary alveolar macrophages and macrophage surrogates. BMC Immunology. 13(1). 57–57. 43 indexed citations
17.
Kent, Toby, et al.. (2007). G-protein-coupled receptor heterodimerization: assay technologies to clinical significance.. PubMed. 10(5). 580–9. 13 indexed citations
18.
Kent, Toby, Kevin S. J. Thompson, & Louise H. Naylor. (2005). Development of a Generic Dual-Reporter Gene Assay for Screening G-Protein-Coupled Receptors. SLAS DISCOVERY. 10(5). 437–446. 9 indexed citations
19.
Kemp, Daniel M., et al.. (2002). The Effect of ICER on Screening Methods Involving CRE-Mediated Reporter Gene Expression. SLAS DISCOVERY. 7(2). 141–148. 9 indexed citations
20.
Kemp, Daniel M., et al.. (2002). The Effect of ICER on Screening Methods Involving CRE-Mediated Reporter Gene Expression. 7(2). 141–148. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James Harrison Breakdown of academic impact, for papers by Guillaume Arguin Breakdown of academic impact, for papers by Elena Calama Breakdown of academic impact, for papers by Margaret Nguyen Breakdown of academic impact, for papers by Håkan Bergstrand Breakdown of academic impact, for papers by Anja Herrnreiter Breakdown of academic impact, for papers by Valerie C. Lowe Breakdown of academic impact, for papers by Paul C. Canniff Breakdown of academic impact, for papers by Hana Yamane Breakdown of academic impact, for papers by M A Giembycz
Rankless by CCL
2026